MPL and JAK2V617F mutation analysis was performed in 603 patients with primary myelofibrosis (PMF) seen at the Mayo Clinic, USA (n ¼ 329) or University of Florence, Italy (n ¼ 274). Mutant MPL was detected in 49 (8.1%) patients and JAK2V617F in 350 (58%); 4 patients showed both mutations. MPLW515L/K was the commonest mutation; 2 patients showed novel mutations (L513ins and Q516-P518insAAAA). The US and Italy patient cohorts were separately analyzed for comparison of survival and clinical features between MPL-mutated, JAK2-mutated and JAK2/MPL-unmutated cases. JAK2/MPLunmutated patients were significantly younger than their JAK2-mutated counterparts, in both patient cohorts (Po0.01). In the Florence only cohort, the presence of mutant MPL was associated with older age (Po0.01) and constitutional symptoms (P ¼ 0.04) and JAK2V617F with higher hemoglobin (Po0.01) and leukocyte (P ¼ 0.03) count; neither patient cohort showed significant associations with platelet count, hemoglobin o10 g/dl, abnormal/unfavorable karyotype, spleen size or prognostic score distribution. To date, 240 deaths and 79 leukemic transformations have been documented among all 603 study patients. Multivariable analysis disclosed no significant difference in overall or leukemia-free survival between the three molecular subgroups. We conclude that the presence of mutant MPL has narrow and inconsistent phenotypic effect in PMF and does not influence overall or leukemia-free survival.
Introduction
The BCR-ABL1-negative myeloproliferative neoplasms, including polcythemia vera, essential thrombocythemia (ET) and primary myelofibrosis (PMF), are stem cell-derived clonal or oligoclonal hemopathies that can display a complex clonal structure and mutational hierarchy. 1 In molecular terms, polcythemia vera is probably the best characterized, with B96 and 3% of affected patients harboring mutations in exon 14 (JAK2V617F) and exon 12 of JAK2, respectively. 2, 3 JAK2V617F occurs less frequently in ET and PMF, with a mutation prevalence of B55% and 65%, respectively. 3 Mutations in the juxtamembrane domain of the thrombopoietin receptor MPL occur in B4% of ET patients and 8% of those with PMF; [4] [5] [6] [7] MPL mutations have also been described in acute megakaryoblastic leukemia, refractory anemia with ring sideroblasts and thrombocytosis and myelodysplastic syndrome with del(5q). [8] [9] [10] Although the vast majority of MPL mutations are missense mutations in exon 10 that result in the substitution of Trp (W) at position 515 by either Leu (L), Lys (K), Arg (R) or Ala (A), other infrequent mutant alleles such as W515-P518delinsKT have also been described. 4, 11, 12 Although the MPLS505N allele has been identified previously as an inherited mutation in cases of familial thrombocythemia, 13 it can also apparently be acquired as a somatic event in ET patients. 4 There are limited data on the phenotypic associations of mutant MPL in myeloproliferative neoplasms. In ET, MPL mutation presence may not define a distinct clinicopathologic entity and has limited prognostic significance in terms of thrombosis, leukemic or fibrotic transformation or survival. 4, 7 In PMF, the presence of MPL mutation was associated with older age, female gender, lower hemoglobin level and greater need for red cell transfusions; however, its impact on clinical outcome was not addressed. 5 In this study involving two large cohorts of PMF patients, we describe the clinical and laboratory characteristics of MPL-mutated patients, as compared with those harboring JAK2V617F or neither mutation. We also investigated the prognostic impact of mutant MPL on overall and leukemiafree survival.
Materials and methods
This study was approved by the Mayo Clinic/University of Florence institutional review boards. All patients provided informed written consent for study sample collection as well as permission for its use in research. Inclusion to this study required availability of archived peripheral blood or bone marrow sample collected at the time of diagnosis or first referral; a total of 329 PMF patients and 274 PMF patients met these stipulations at Mayo Clinic and University of Florence, respectively, thereby allowing for determination of MPL and JAK2V617F mutation status in a total of 603 patients. 14 The diagnoses of PMF and leukemic transformation were according to the World Health Organization criteria. 15 Unfavorable karyotype designation and Dynamic International Prognostic Scoring System-plus (DIPSS-plus) risk categorization for Mayo Clinic patients were as previously described. [16] [17] [18] University of Florence patients were classified per the International Prognostic Scoring System (IPSS). 19 Screening of Mayo Clinic patients for MPL exon 10 genetic variations was performed using the high-resolution melting dye assay using the LightCycler 480 Instrument (Roche Applied Science, Mannheim, Germany). For each 20 ml reaction, 15-30 ng of DNA template was added to a reaction mixture of 1.5 mM MgCl 2 , 500 nM of both forward and reverse primer (MPLforward 5 0 -TAGCCTGGATCTTCTCCTTGGTG-3 0 ; MPL-reverse 5 0 -GCGGTACCTGTAGTGTGCAG-3 0 ), ddH 2 O and 1 Â of enzyme mix (HRM Master Kit, Roche). Each reaction was first amplified by real-time PCR using the following cycling parameters: 95 1C for 10 min followed by 45 cycles of 95 1C for 10 s, 60 1C for 15 s and 72 1C for 30 s. After amplification, each target sequence was subjected to an increasing temperature and data from the intercalated high-resolution melting dye signal resulting from dissociation of double-stranded DNA to single-stranded DNA were plotted. Analysis of melting curves was executed using Gene Scanning Software (Roche) and was normalized to wild-type sequence. Any sample sequence that deviated from the normal plot was Sanger sequenced for confirmation of presence of MPL genetic variation. Sequencing was performed bidirectionally using two ABI PRISM 3730xl DNA analyzers (96-capillary) (Applied Biosystems, Carlsbad, CA, USA). University of Florence patients were screened for presence of MPLW515L/K mutations using a previously described real-timePCR assay (sensitivity for mutant allele 0.1%) based on locked nucleic acid probes. 20 All mutations were confirmed by direct DNA sequencing. JAK2V617F mutation screening was performed as described previously. 
Results
A total of 603 patients with PMF were studied and the study population consisted of two large patient cohorts from the Mayo Clinic, USA (n ¼ 329) and University of Florence, Italy (n ¼ 274). The two patient cohorts were independently analyzed for comparison of clinical features, overall survival and leukemiafree survival between MPL-mutated, JAK2-mutated and JAK2/ MPL-unmutated cases.
Mayo Clinic (US) cohort
The Mayo cohort consisted of 329 PMF patients (median age, 63 years; range 14-83 years; 65% males) who had peripheral blood and/or bone marrow sample collected and stored for research purposes at the time of their first referral to our institution (Table 1 ). Of these, 192 patients (59%) were seen within the first year of PMF diagnosis; the presenting clinical and laboratory characteristics of this subgroup are presented separately in Table 2 . A complete record of prior treatment was available for 288 patients at the time of referral; 86 patients (30%) had received prior PMF-directed therapy, of which 46 patients (16%) had received cytoreductive therapy. The Dynamic International Prognostic Scoring System plus (DIPPS-plus) 17 risk distribution was as follows: low risk (n ¼ 35; 11%), intermediate-1-risk (n ¼ 86; 26%), intermediate-2-risk (n ¼ 143; 44%) and high risk (n ¼ 63; 19%). Overall, Table 1 Clinical and laboratory characteristics for 329 Mayo primary myelofibrosis patients stratified on the basis of JAK2V617F and MPL exon 10 mutation status: (i) JAK2 mutated; (ii) MPL mutated and (iii) unmutated 94 patients (32%) showed a need for red cell concentrate transfusions at referral; other information relevant to disease risk, including the proportion with abnormal karyotype and thrombocytopenia, is presented in Tables 1 and 2 . Of the total 329 patients, 25 (7.6%) harbored MPL exon 10 mutations: W515L was the commonest mutation, seen in 18 (72%) patients; 4 patients (16%) had W515K, 1 patient (4%) had W515R, and 2 patients (8%) had novel mutations (L513ins and Q516-P518insAAAA). In every instance, the MPL mutation was present in the heterozygous state, and none of the patients harbored more than one MPL mutant allele. In the Mayo cohort, 182 patients (55%) were found to harbor the JAK2V617F mutation; however, none of the 25 MPL-mutated cases showed the JAK2V617F mutation concurrently. The aforementioned mutational analysis allowed for classification of patients into three discrete molecular subgroups: (i) MPL mutated; (ii) JAK2 mutated and (iii) MPL/JAK2 unmutated (Tables 1 and 2 ).
All patients
When all 329 PMF patients were analyzed, JAK2-mutated patients were noted to be significantly older as compared with MPL-mutated or MPL/JAK2-unmutated patients (Po0.0001; Table 1 ). There was no significant difference between the three molecular subgroups in terms of DIPSS plus risk category (P ¼ 0.5), median hemoglobin value (P ¼ 0.9), platelet count (P ¼ 0.09) or the proportion of patients with hemoglobin o10 g/dl (P ¼ 0.9) or those needing red cell concentrate transfusions (P ¼ 0.4). The results of phenotype correlation studies were remarkably similar when restricted to either the 192 PMF patients seen within the first year of diagnosis (Table 2) or the 202 treatment-naïve patients (data not shown).
Median follow-up from the time of mutation analysis for the overall cohort was 36.4 months (range, 0.1-291.9 months); during this period, 185 deaths (56%) and 35 leukemic transformations (11%) were documented (Table 1) .
On univariate analysis, JAK2-mutated PMF patients significantly inferior survival as compared with their MPL-mutated or MPL/JAK2-unmutated counterparts (P ¼ 0.03; Figure 1) ; however, JAK2-mutated status failed to retain its significance when age (either as a continuous variable or a dichotomous o60 vs X60 years variable) was included as a covariate in multivariable analysis (P ¼ 0.6). In other words, the difference in survival was all accounted for by the fact that JAK2-mutated patients were significantly older than MPL-mutated or unmutated patients. An analysis restricted to the 192 PMF patients studied within a year of diagnosis (median follow-up of 47.5 months; range, 0.5-291.9 months) yielded similar results (P ¼ 0.04; Figure 2) ; here also, age accounted for the adverse prognostic impact of JAK2-mutated status on overall survival (P ¼ 0.3). There was no significant difference in leukemia-free survival for patients stratified by MPL-or JAK2-mutated status (P ¼ 0.5; Figure 3 ).
University of Florence (Italy) cohort
A total of 274 patients were studied for the presence of MPLW515L/K and JAK2V617F mutations, within 1 year of diagnosis and before any therapeutic intervention. Twenty-four patients (8.8%) were found to harbor MPL mutations; of these, four patients showed both MPL and JAK2V617F mutations and were excluded from subsequent analysis. Data for the remaining 270 patients classified into MPL-mutated (n ¼ 20), JAK2-mutated (n ¼ 164) and MPL/JAK2-unmutated (n ¼ 86) subgroups are presented in Table 3 . Thirteen patients harbored the MPLW515L mutation and seven patients had MPLW515K. The presence of mutant MPL was associated with older age (Po0.01) and constitutional symptoms (P ¼ 0.04) and JAK2V617F with higher hemoglobin (Po0.01) and leukocyte (P ¼ 0.03) count. There were no significant differences between the three molecular Table 2 Clinical and laboratory characteristics for 192 Mayo primary myelofibrosis patients studied within 1 year of their diagnosis and stratified on the basis of JAK2V617F and MPL exon 12 mutation status: (i) JAK2 mutated; (ii) MPL mutated and (iii) unmutated subgroups in terms of IPSS risk distribution, proportion with hemoglobin o10 g/dl, platelet count, spleen size or incidence of abnormal karyotype (Table 3) . After a median follow-up of 26.9 months (range 1-340), 55 deaths (21%) and 44 leukemic transformations (17%) were recorded (Table 3) . There was no difference in overall survival (P ¼ 0.2) or leukemia-free survival (P ¼ 0.9) when comparing MPL-mutated vs JAK2-mutated vs MPL/JAK2-unmutated subgroups (Figures 4 and 5) .
Discussion
Although the prevalence of MPL exon 10 mutations in PMF has been reported previously by us 6 and others, 5 the impact of MPL mutation presence on long-term clinical outcome, in particular the risk of leukemic transformation and premature death, has remained obscure in this patient population. In this paper, we report on the largest series of MPL-mutated PMF patients; in addition to allowing for correlation of mutant allele presence with the clinical and laboratory features of PMF, this relatively mature dataset allowed for correlation of MPL mutation with overall and leukemia-free survival, which represent novel observations.
For the 603 patients, the frequency of MPL mutations was slightly greater (8.1%) as compared with our previous report of 159 patients (5%), 6 but was remarkably similar to another study of 217 myelofibrosis patients (8%). 5 Overall, the frequency of MPL exon 10 mutations in PMF (B8%) appears to be roughly twice that observed in ET patients (B4%). 4, 7 Similar to what has been observed in ET, 7 the frequency of MPL mutations was similar in the Mayo cohort patients studied within a year of diagnosis (8%) or later (7%), suggesting that MPL mutations are present at the time of PMF diagnosis rather than being acquired later during the course of the disease. Of the Mayo cohort, none of the 25 MPL-mutated patients showed the JAK2V617F mutation concurrently. In contrast, 4 of 25 patients (17%) in the University of Florence cohort exhibited both mutations concurrently. The latter observation is similar to earlier reports by Guglielmelli et al. 5 (4 of 18 MPL-mutated myelofibrosis patients; that is, 22% mutation concurrence) and Pardanani et al. 6 (3 of 8 MPL-mutated PMF patients; that is, 38% mutation concurrence). The difference in estimates of MPL and JAK2 mutation concurrence in the aforementioned papers likely reflects the relatively small patient numbers and underlying patient heterogeneity, rather than differences in screening assay sensitivity. In the current paper, Mayo patients were screened for JAK2V617F using an allele-specific PCR with 1% sensitivity; 14 however, it cannot be entirely excluded that the use of a more sensitive assay (0.1-0.01% sensitivity) may have identified JAK2V617F at low level in some MPL-mutated PMF cases in that cohort. On a similar note, of the 411 JAK2V617F-positive ET cases enrolled in the MRC PT-1 study, only 1 patient harbored a 
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Overall survival Figure 1 Survival data for 329 Mayo primary myelofibrosis patients stratified on the basis of JAK2V617F and MPL exon 10 mutation status: (i) JAK2 mutated; (ii) MPL mutated and (iii) unmutated. On univariate analysis, JAK2-mutated patients (n ¼ 182; median survival B49 months) had a significantly inferior survival as compared with MPLmutated (n ¼ 25; median survival B65 months) or unmutated (n ¼ 122; median survival B73 months) patients (P ¼ 0.03). On multivariable analysis that included age as a covariate (either as a continuous variable or as a dichotomous variable, that is, o vs X60 years), the prognostic impact of JAK2-mutated status on overall survival was lost (P ¼ 0.6). 
Leukemia-free survival
Follow-up (months) Figure 3 Leukemia-free survival data for 329 Mayo primary myelofibrosis patients stratified on the basis of JAK2V617F and MPL exon 10 mutation status: (i) JAK2 mutated; (ii) MPL mutated and (iii) unmutated. There was no significant difference in leukemia-free survival for the three molecular subgroups (P ¼ 0.5).
MPL exon 10 mutation concurrently with JAK2V617F. 4 Based on the aforementioned, it seems reasonable to conclude that a small number of MPL-mutated PMF or ET patients may harbor the JAK2V617F mutation concurrently.
In the current paper, we focused on comparing clinical/ laboratory characteristics for the three PMF molecular subgroups, namely MPL mutated, JAK2 mutated and MPL/JAK2 unmutated. There appeared to be no consistent correlation between MPL mutation presence and particular PMF phenotypic feature(s); in particular, the Mayo cohort data failed to confirm the association between MPL mutations and significantly lower hemoglobin level and higher red cell concentrate transfusion dependency that was noted in the University of Florence cohort. In ET, two independent studies have confirmed that MPL-mutated patients have significantly lower hemoglobin levels and higher platelet counts as compared with JAK2V617F-positive patients, but not JAK2V617F-negative patients. 4, 7 In contrast, the two studies to date in myelofibrosis patients (this study and that by Guglielmelli et al.), 5 have revealed no significant difference in the platelet count between MPL-mutated and MPL-wild-type patients. Figure 5 Leukemia-free survival data for 253 University of Florence primary myelofibrosis patients stratified on the basis of JAK2V617F and MPLW515L/K mutation status: (i) JAK2 mutated; (ii) MPL mutated and (iii) unmutated. There was no significant difference in leukemia-free survival among the three groups (P ¼ 0.9).
In this study, the presence of MPL mutation had no impact on either overall survival or leukemia-free survival in PMF. This observation combined with the limited phenotypic effect of mutant MPL is consistent with the view that MPL mutations provide an alternate mechanism for activating JAK-STAT, akin to JAK2V617F, rather than represent a fundamentally different process in terms of underlying disease pathophysiology. Similarly, it is reasonable to assume that 'MPL/JAK2-unmutated' PMF patients harbor either phenocopy mutations (for example LNK), 22, 23 or yet unidentified mutant alleles that also constitutively activate JAK-STAT signaling.
From a practical standpoint, the observations from this study greatly undermine the value of MPL mutation analysis for prognostic purposes, in the setting of PMF, and also confirm the similar lack of prognostic relevance attached to the mere presence or absence of JAK2V617F. Whether or not measurement of MPL mutant allele burden would produce different results, as had been the case with JAK2V617F allele burden measurement, 14, 24 remains to be shown.
